Your Health, We Care
Release date: 2024-08-26 17:10:34 Recommended: 162
Alpelisib is the first PI3Kα inhibitor to be used in combination with fulvestrant for the treatment of HR/HER2- breast cancer. By targeting the PIK3CA mutation, Alpelisib significantly prolongs the patient's progression-free survival and reduces the risk of disease progression.
The dosage requirements listed in this article are based on the instructions of the drug, and the specific use of Alpelisib should be adjusted according to the doctor's recommendations.
The standard dose of Alpelisib is 300 mg, which is two 150 mg film-coated tablets. It is recommended to take it once a day, preferably with a meal, to improve the absorption of the drug.
When using Alpelisib, the recommended dose of fulvestrant is 500 mg each on days 1, 15, and 29, and monthly thereafter. For detailed medication instructions, see the full prescribing information for fulvestrant.
The above doses are appropriate for most patients, but dosing regimens may vary for special populations. The considerations for the use of Alpelisib in specific populations are discussed below.
When using Alpelisib in special populations, the dose and regimen need to be adjusted on a case-by-case basis.
Before using apelix, it is important to check whether a woman is pregnant. During treatment and for a week after taking the drug, women should use effective contraception, and male partners should also use contraception. Animal studies have shown that this medicine may have an effect on fertility.
Studies have shown a higher incidence of hyperglycemia in patients over 65 years of age with the use of Alpelisib, but there is no significant difference in efficacy. For patients over 75 years of age, there are insufficient data to fully assess drug efficacy.
When considering the use of apellibus, it is also important to note the effects of drug interactions.
Alpelisib may interact with other medications, affecting efficacy or increasing the risk of adverse effects.
The combination of Alpelisib with strong CYP3A4 inducers may reduce the concentration of Alpelisib and reduce the efficacy of the drug. Concomitant use of strong CYP3A4 inducers should be avoided and alternative agents with less impact on CYP3A4 should be considered.
To ensure therapeutic efficacy and reduce adverse effects, patients should pay close attention to interactions with other drugs during medication.
[Warm tips] Be sure to follow your doctor's instructions while using Alpelisib, especially when it comes to drug interactions. Regular monitoring and inspection is an important measure to ensure the effectiveness of treatment and reduce adverse effects.
